Vistagen Therapeutics, Inc.

NasdaqCM:VTGN Stock Report

Market Cap: US$81.7m

Vistagen Therapeutics Future Growth

Future criteria checks 2/6

Vistagen Therapeutics is forecast to grow earnings and revenue by 9.5% and 60.1% per annum respectively while EPS is expected to grow by 17.1% per annum.

Key information

9.5%

Earnings growth rate

17.1%

EPS growth rate

Biotechs earnings growth27.3%
Revenue growth rate60.1%
Future return on equityn/a
Analyst coverage

Low

Last updated08 Nov 2024

Recent future growth updates

Recent updates

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Sep 08

VistaGen drops 80% as late-stage study for anxiety therapy fails

Jul 22

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10
Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

VistaGen Therapeutics added to Russell 2000 Index

Jun 16

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

VistaGen initiates late-stage trial of PH94B in social anxiety disorder

May 26

VistaGen names new chief commercial officer

May 04

How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

Feb 16
How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

VistaGen Therapeutics regains Nasdaq listing compliance

Jan 06

VistaGen Therapeutics slumps in after hours trade on underwritten public offering

Dec 17

Earnings and Revenue Growth Forecasts

NasdaqCM:VTGN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20275-90-104-1033
3/31/20260-79-68-674
3/31/20251-57-51-504
9/30/20241-40-34-33N/A
6/30/20241-33-29-29N/A
3/31/20241-29-26-26N/A
12/31/20231-32-26-26N/A
9/30/20231-35-31-31N/A
6/30/20230-46-42-42N/A
3/31/20230-59-50-50N/A
12/31/20220-64-58-58N/A
9/30/20220-65-60-60N/A
6/30/20221-60-55-55N/A
3/31/20221-49-45-45N/A
12/31/20212-62-35-35N/A
9/30/20211-56-28-28N/A
6/30/20211-47-16-15N/A
3/31/20211-42-12-12N/A
12/31/20201-16-10-9N/A
9/30/20200-17-9-9N/A
6/30/2020N/A-19-14-14N/A
3/31/2020N/A-22-16-16N/A
12/31/2019N/A-24-17-17N/A
9/30/2019N/A-26-16-16N/A
6/30/2019N/A-28-16-16N/A
3/31/2019N/A-26-15-15N/A
12/31/2018N/A-24-14-14N/A
9/30/2018N/A-20-12-12N/A
6/30/2018N/A-18N/A-10N/A
3/31/2018N/A-16N/A-9N/A
12/31/2017N/A-14N/A-8N/A
9/30/20171-13N/A-7N/A
6/30/20171-12N/A-8N/A
3/31/20171-12N/A-7N/A
12/31/20161-18N/A-7N/A
9/30/2016N/A-19N/A-6N/A
6/30/2016N/A-24N/A-6N/A
3/31/2016N/A-51N/A-5N/A
12/31/2015N/A-48N/A-4N/A
9/30/2015N/A-46N/A-4N/A
6/30/2015N/A-39N/A-3N/A
3/31/2015N/A-14N/A-3N/A
12/31/2014N/A-9N/A-2N/A
9/30/2014N/A-8N/A-2N/A
6/30/2014N/A-8N/A-2N/A
3/31/2014N/A-3N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VTGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VTGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VTGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VTGN's revenue (60.1% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: VTGN's revenue (60.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VTGN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y